A Cure for Mesothelioma? Hopes High for New Cancer Vaccine

Researchers at Stanford University are about to move into human trials of what some believe may be the most promising treatment yet for malignant mesothelioma and other types of solid tumors. The new treatment is an immunotherapy vaccine that combines two separate agents, both of which are already being tested independently.   Unlike some other types of immunotherapy – including drugs like Keytruda and Opdivo … Continue reading A Cure for Mesothelioma? Hopes High for New Cancer Vaccine »

Could Stem Cell Vaccine Lead to Mesothelioma Cure?

woman mesothelioma doctor holds syringe

A new stem cell vaccine that has proven effective against malignant mesothelioma and several other cancers in mice might offer a promising new way to treat the asbestos cancer. Although rare, malignant mesothelioma is one of the most treatment-resistant malignancies. Even with aggressive therapies, most people diagnosed with mesothelioma do not survive longer than about 18 months. But research conducted at Stanford University and published in … Continue reading Could Stem Cell Vaccine Lead to Mesothelioma Cure? »

Mayo Researchers Fight Mesothelioma with Measles Virus

The same virus that can make unvaccinated children come down with spots and fevers may provide the basis for a powerful new weapon against the intractable cancer, malignant pleural mesothelioma. New research being conducted at the University of Minnesota and the Mayo Clinic suggests that a strain of the measles virus called MV-Edm (the Edmonston strain) has the unique ability to not only target and … Continue reading Mayo Researchers Fight Mesothelioma with Measles Virus »

Fast-Tracked Mesothelioma Drug Set for Phase 3 Trials

woman mesothelioma doctor holds syringe

By this time next year, a pivotal Phase 3 trial will be underway on what looks to be one of the most promising new therapies for malignant pleural mesothelioma.   The makers of galinpepimut-S, an immunotherapy vaccine with Orphan Drug status for acute myeloid leukemia and pleural mesothelioma, recently announced their intention to begin the Phase 3 mesothelioma trial in mid-2017. The news was punctuated by … Continue reading Fast-Tracked Mesothelioma Drug Set for Phase 3 Trials »

Enzyme Blockers May Offer Innovative New Mesothelioma Treatment

physician

Cancer drugs that block an enzyme called EZH2 could be a “tremendous innovation” for mesothelioma patients, according to researchers at Memorial Sloan Kettering Cancer Center in New York. Recent research on mice at Memorial Sloan Kettering found that elevated levels of EZH2 allowed mesothelioma to grow out of control and that blocking the enzyme inhibited the growth of mesothelioma tumors. A New Kind of Mesothelioma … Continue reading Enzyme Blockers May Offer Innovative New Mesothelioma Treatment »

New Immunotherapy for Mesothelioma Relies on Altered T-Cells

An emerging type of mesothelioma therapy that uses altered T-cells to attack tumors is generating some excitement among researchers at Memorial Sloan Kettering Cancer Center in New York. The approach, called CAR T-cell therapy, produces what the National Cancer Institute has called a “living drug” for targeted mesothelioma treatment. A new review of this immunotherapy approach has some encouraging news for mesothelioma patients and their … Continue reading New Immunotherapy for Mesothelioma Relies on Altered T-Cells »

Immunotherapy Drug: More May be Better for Advanced Mesothelioma

The same team of Italian researchers that first reported on the safety and efficacy of the immunotherapy drug tremelimumab for mesothelioma now say that giving more of the drug might be even more effective. Tremelimumab is a monoclonal antibody that acts on a particular downregulator of the immune system called cytotoxic T-lymphocyte antigen 4 (CTLA4). The goal of tremelimumab is to inhibit the immune system … Continue reading Immunotherapy Drug: More May be Better for Advanced Mesothelioma »

Mesothelioma Vaccine Receives Orphan Drug Approval

woman mesothelioma doctor holds syringe

Mesothelioma patients who are not candidates for surgery may soon have another treatment option. The FDA has granted orphan drug approval to a new cancer vaccine called CRS-207. CRS-207 is manufactured by Aduro Biotech, Inc. and is made from an attenuated (less potent) version of the bacteria Listeria monocytogenes. CRS-207 triggers a powerful immune response against cells that produce mesothelin, a tumor-associated antigen produced by … Continue reading Mesothelioma Vaccine Receives Orphan Drug Approval »

Australian Doctors Use Bacteria to Shrink Mesothelioma Tumors

Could bacteria responsible for problems ranging from sinusitis to food poisoning be used as a weapon in the fight against malignant mesothelioma? The results of a new study conducted by mesothelioma researchers at the University of Western Australia suggest that it might. The researchers focused their study on a compound made up of proteins produced by the bacteria Staphylococcus aureus, also called ‘Staph’ bacteria. The … Continue reading Australian Doctors Use Bacteria to Shrink Mesothelioma Tumors »

Mesothelioma Vaccine Enters Phase 2 Testing

The makers of a new cancer vaccine say they have enrolled the first mesothelioma patients in a study that will combine their drug with chemotherapy against this virulent cancer. The drug, currently known as CRS-207, is manufactured by Aduro Bio Tech, Inc. According to a company press release, CRS-207 is based on an attenuated (made less potent) version of Listeria monocytogenes, bacteria found in soil and water … Continue reading Mesothelioma Vaccine Enters Phase 2 Testing »

Get your free copy of
“Surviving Mesothelioma” Today!